Distribution · Contracts

What to include in a pharmaceutical distribution agreement

A pharmaceutical distribution agreement should set commercial terms such as territory, term, minimum purchase and termination, alongside quality clauses required by good distribution practice: a written outsourcing contract covering compliance with GDP, complaint and recall handling, subcontracting approval and periodic audits, plus a legal review before signing.

Most of what goes into a distribution agreement is ordinary commercial practice, not regulation. But good distribution practice guidance from WHO and the European Commission does reach into the contract, because appointing a distributor is, in regulatory terms, outsourcing an activity that affects product quality. This guide separates the two, what the guidelines specifically require, and what is left to negotiation.

Why does a commercial agreement need regulatory clauses at all?

Because handing distribution to another party is, under good distribution practice guidance, an outsourced activity, and outsourcing an activity does not outsource the responsibility for it. EU GDP guidance states that any outsourced activity covered by the GDP guide should be correctly defined, agreed and controlled to avoid misunderstandings that could affect product integrity, and that there must be a written contract between the contract giver and the contract acceptor clearly establishing each party's duties.¹ WHO guidance is just as direct: any storage or distribution activity delegated to another party should be performed by appropriately authorised parties, under national legislation and the terms of a written contract.² A manufacturer appointing a distributor is, in effect, the contract giver in both frameworks.

What does WHO guidance say the contract must define?

WHO Technical Report Series No. 1025, Annex 7, section 19 is specific about the minimum content. The written contract should define the responsibilities of each entity, the contract giver and the contract acceptor, and cover at least: compliance with the guideline and the principles of GSP and GDP; measures to keep substandard and falsified products out of the distribution chain; training of personnel; subcontracting conditions subject to the contract giver's written approval; and periodic audits.² The contract giver should assess the contract acceptor beforehand, for example through on-site audits, documentation and licensing status review, and provide all relevant product information; the contract acceptor should have adequate premises, equipment, personnel, knowledge, experience and vehicles, and should refrain from any activity that could adversely affect the products handled.²

What does EU GDP guidance add about the two parties' duties?

The same division of responsibility, in more detail. The contract giver is responsible for the outsourced activities, for assessing the contract acceptor's competence, and for ensuring, through the contract and through audits, that GDP is followed; an audit should be performed before the activities begin and after any change, with frequency set by risk.¹ The contract acceptor should have adequate premises, procedures and competent personnel, must not pass any contracted work to a third party without the contract giver's prior approval and an audit of that third party, and must forward any information that could affect product quality.¹ In practice, this means naming who audits whom, on what schedule, and requiring written consent before any part of the work is passed to someone else.

What should the agreement say about complaints, returns and recalls?

That they are recorded and handled under written procedures, consistently across the supply chain. EU GDP guidance frames this as one principle: all complaints, returns, suspected falsified products and recalls must be recorded and handled carefully under written procedures, with records available to the competent authorities.¹ Within that, the contract should assign specific duties: a named person to handle complaints, with quality complaints passed to the manufacturer without delay¹; returns handled under a written, risk-based process reflecting the product, its storage needs and time since dispatch¹; suspected falsified products reported immediately to the competent authority and the marketing authorisation holder¹; and recall arrangements evaluated at least annually, so a recall can be initiated promptly and the distributor follows the recall instructions.¹

What belongs in the agreement beyond the quality clauses?

The larger part of most distribution agreements, in practice. Territory and exclusivity, the length of the term and renewal conditions, minimum purchase or sales commitments, pricing and currency, expected stock cover and lead times, and what happens to product registrations if the parties later separate are all standard commercial terms. None of this comes from the guidance above, it is common industry practice, and it deserves the same care as the quality clauses: vague territory wording or a silent registration clause causes as much damage on separation as a missing audit right does during the relationship.

Does Yemen have its own requirements for these agreements?

Not one published, fixed list. As with other regulatory specifics in Yemen, requirements are confirmed case by case, and much of what circulates online about registration and local agreements comes from consultancies whose accounts contradict each other. Rather than state an unverified Yemen-specific rule here, the honest position is to check directly with a party licensed in the market. LNJC is a licensed importer and distributor of pharmaceuticals, medical supplies, laboratory equipment, pharmaceutical raw materials and packaging materials in the Republic of Yemen, based in Sana'a, and, under signed agreements, exclusive distributor in the Republic of Yemen for the products named in those agreements from Shivani Scientific Industries Pvt. Ltd. (India) and Zhanjiang Bokang Marine Biological Co., Ltd. (BOKANG BIO, China). We are glad to talk a manufacturer through what a Yemen agreement should contain before any commitment is made. For how a candidate distributor is vetted before that agreement is drafted, see what to check before you appoint a distributor.

Should the agreement be reviewed by a lawyer?

Yes. Nothing in this guide is legal advice, and a distribution agreement should be reviewed by someone qualified in the relevant jurisdictions before signature, particularly the commercial terms and the registration and termination provisions that sit outside the good distribution practice guidance cited above.

In summary

A pharmaceutical distribution agreement carries two kinds of obligation. WHO and EU good distribution practice guidance requires a written contract defining responsibilities for compliance, anti-falsification measures, training, subcontracting approval and audits, and assigning complaint, return and recall duties by name. Alongside that, ordinary commercial terms, territory, term, pricing, stock cover, and what happens to registrations on separation, need the same clarity. Have both reviewed by someone qualified before you sign, and see the fuller set of questions to ask before you choose a partner for what comes before the contract itself.